We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-7.84%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$375M
AUM Growth
-$122M
Cap. Flow
-$59.9M
Cap. Flow %
-16%
Top 10 Hldgs %
61.48%
Holding
38
New
4
Increased
8
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$14.2M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$10.5M
3
CBAY
Cymabay Therapeutics
CBAY
+$8.1M
4
GPCR icon
Structure Therapeutics
GPCR
+$7.44M
5
VKTX icon
Viking Therapeutics
VKTX
+$4.65M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$47.8M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$38.6M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$23.9M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$5.52M
5
KALV
KalVista Pharmaceuticals
KALV
+$1.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$69.2M 18.48%
7,648,268
– –
OLMA icon
2
Olema Pharmaceuticals
OLMA
$899M
$22.9M 6.12%
1,857,681
+1,395,181
+302% +$14.2M
GERN icon
3
Geron
GERN
$970M
$22.7M 6.06%
10,712,481
+1,521,191
+17% +$4.13M
RPTX
4
DELISTED
Repare Therapeutics
RPTX
$19.8M 5.29%
1,639,849
– –
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
$19.1M 5.1%
1,745,943
– –
NTLA icon
6
Intellia Therapeutics
NTLA
$1.8B
$17.2M 4.6%
544,639
– –
MLTX icon
7
MoonLake Immunotherapeutics
MLTX
$1.28B
$16.8M 4.48%
294,190
-921
-0.3% -$50.8K
IOVA icon
8
Iovance Biotherapeutics
IOVA
$3.63B
$15M 3.99%
3,287,397
+337,279
+11% +$2.2M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$9B
$14.2M 3.8%
479,053
– –
INSM icon
10
Insmed
INSM
$25.9B
$13.3M 3.56%
527,458
-2,285
-0.4% -$52.3K
GPCR icon
11
Structure Therapeutics
GPCR
$3.38B
$11.6M 3.11%
+230,761
New +$7.44M
VERV
12
DELISTED
Verve Therapeutics
VERV
$11.4M 3.04%
857,940
– –
RLAY icon
13
Relay Therapeutics
RLAY
$4.11B
$11.4M 3.04%
1,352,133
-2,235
-0.2% -$24K
RGNX icon
14
Regenxbio
RGNX
$638M
$10.8M 2.89%
656,718
– –
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$9.11M 2.43%
+610,770
New +$8.1M
KRTX
16
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9M 2.4%
53,210
-189
-0.4% -$35.5K
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
$8.71M 2.32%
716,139
+200,000
+39% +$2.58M
RVMD icon
18
Revolution Medicines
RVMD
$44.6B
$7.57M 2.02%
273,408
– –
XERS icon
19
Xeris Biopharma Holdings
XERS
$1.55B
$7.42M 1.98%
3,987,967
+12,968
+0.3% +$29.7K
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
$6.84M 1.83%
664,224
+279,234
+73% +$3.74M
AXSM icon
21
Axsome Therapeutics
AXSM
$10.4B
$6.54M 1.75%
93,586
– –
MDGL icon
22
Madrigal Pharmaceuticals
MDGL
$12.3B
$5.97M 1.59%
40,859
+2,848
+7% +$536K
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$5.57M 1.49%
577,958
-183,580
-24% -$1.88M
HOWL icon
24
Werewolf Therapeutics
HOWL
$45.8M
$5.11M 1.36%
2,388,011
– –
TVTX icon
25
Travere Therapeutics
TVTX
$6.19B
$4.94M 1.32%
552,846
– –
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2023 Portfolio in Review

As of Q3 2023, MPM BioImpact held 38 positions worth $375M, down 25% from $497M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

MPM BioImpact withdrew a net $59.9M in Q3 2023, closing 6 positions and reducing 6 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $47.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, MPM BioImpact opened a new position in Morphic Holding, Inc. Common Stock worth $4.58M.

  • MPM BioImpact's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 200,000 shares worth $4.58M.
  • MPM BioImpact added most to Olema Pharmaceuticals in Q3 2023, an estimated $14.2M increase.
  • MPM BioImpact's biggest Q3 2023 reduction was KalVista Pharmaceuticals, cutting an estimated $1.88M.
  • MPM BioImpact fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
  • MPM BioImpact's ten largest holdings make up 61% of its $375M portfolio in Q3 2023.
  • MPM BioImpact opened 4 new positions and closed 6 in Q3 2023.
  • MPM BioImpact's portfolio value fell 25% quarter-over-quarter to $375M.

Based on MPM BioImpact's 13F filing for Q3 2023, filed 14 Nov 2023.